iMedMS: An IoT Based Intelligent Medication Monitoring System for Elderly Healthcare

Author(s):  
Khalid Ibn Zinnah Apu ◽  
Mohammed Moshiul Hoque ◽  
Iqbal H. Sarker
2010 ◽  
Vol 33 (5) ◽  
pp. 653-660 ◽  
Author(s):  
Jianzhong Hao ◽  
Maniyeri Jayachandran ◽  
Na Ni ◽  
Jiliang Phua ◽  
Hui‐Ming Liew ◽  
...  

1979 ◽  
Vol 3 (3-4) ◽  
pp. 143-151
Author(s):  
Deborah J. Brown ◽  
Richard Domine ◽  
Edward Seward ◽  
Andrew B. Whinston

Author(s):  
Se Jin Park ◽  
Murali Subramaniyam ◽  
Seoung Eun Kim ◽  
Seunghee Hong ◽  
Joo Hyeong Lee ◽  
...  

2020 ◽  
Vol 1529 ◽  
pp. 032061
Author(s):  
Angelina A. Silverio ◽  
Angelito A. Silverio ◽  
Al Mathew Remot

2012 ◽  
Vol 3 (4) ◽  
Author(s):  
Sarah C. Watkins ◽  
Bruce R. Winchester ◽  
Nancy C. Brahm ◽  
Nicole B. Washington

Purpose: The primary goal was to improve medication management oversight for a severely mentally ill (SMI) community-based population by developing a medication monitoring system based on current guidelines to optimize pharmacotherapy and minimize potential medication-related adverse effects. The secondary goal was improvement in coordination of care between healthcare providers. Methods: Guidelines for medication used for psychiatric indications were reviewed. A database of medication for psychiatric indications with monitoring recommendation was developed. Results: Medication regimens for 68 members of the Integrated Multidisciplinary Program of Assertive Community Treatment (IMPACT) program qualified for review. Fourteen medications, carbamazepine, chlorpromazine, clozapine, fluphenazine and fluphenazine long-acting injections (LAI), haloperidol and haloperidol LAI, lithium, lurasidone, olanzapine, paliperidone and paliperidone LAI, perphenazine, quetiapine, risperidone and risperidone LAI, valproic acid/divalproex, and ziprasidone, were identified. In total, 111 medications are used on a monthly basis. Each member receives more than one medication qualifying for review. Additional monitoring parameters that were evaluated included changes in laboratory orders for members with insulin-dependent diabetes. Annual lipid panels were changed to every 6 months, if applicable. Conclusions and Future Directions: This medication monitoring program was developed to help ensure IMPACT members receive the most effective care and minimize potential medication-related adverse effects. The secondary goal was to improve coordination of care. Medication monitoring will be added as a continuous quality assurance measure. Lab results will be reviewed at least monthly. The medication monitoring program will be evaluated annually.   Type: Student Project


Sign in / Sign up

Export Citation Format

Share Document